Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Marie Balsat, Victoria Cacheux, Martin Carre, Emmanuelle Tavernier-Tardy & Xavier Thomas. (2020) Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Expert Review of Anticancer Therapy 20:10, pages 879-891.
Read now
Read now
Jian Yu, Wen Wang & He Huang. (2019) Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis. Hematology 24:1, pages 199-207.
Read now
Read now
Gloria Ravegnini, Giulia Sammarini, Sabrina Angelini & Patrizia Hrelia. (2016) Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia. Expert Opinion on Drug Metabolism & Toxicology 12:7, pages 733-742.
Read now
Read now
Elena Maino, Massimiliano Bonifacio, Anna Maria Scattolin & Renato Bassan. (2016) Immunotherapy approaches to treat adult acute lymphoblastic leukemia. Expert Review of Hematology 9:6, pages 563-577.
Read now
Read now
Muhammad Suleman Khan, Daniel T. Barratt & Andrew A. Somogyi. (2016) Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica 46:3, pages 278-287.
Read now
Read now
Runzhe Chen, Jos L Campbell & Baoan Chen. (2015) Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. OncoTargets and Therapy 8, pages 405-412.
Read now
Read now
Articles from other publishers (32)
Kavita Sangwan, Suman Khurana & Pratibha Dhakla. (2023) Imatinib Analogs in Chronic Myeloid Leukemia: a Systematic Qualitative Review. Current Pharmacology Reports 9:3, pages 99-116.
Crossref
Crossref
Ricardo Sánchez, Sara Dorado, Yanira Ruíz-Heredia, Alejandro Martín-Muñoz, Juan Manuel Rosa-Rosa, Jordi Ribera, Olga García, Ana Jimenez-Ubieto, Gonzalo Carreño-Tarragona, María Linares, Laura Rufián, Alexandra Juárez, Jaime Carrillo, María José Espino, Mercedes Cáceres, Sara Expósito, Beatriz Cuevas, Raúl Vanegas, Luis Felipe Casado, Anna Torrent, Lurdes Zamora, Santiago Mercadal, Rosa Coll, Marta Cervera, Mireia Morgades, José Ángel Hernández-Rivas, Pilar Bravo, Cristina Serí, Eduardo Anguita, Eva Barragán, Claudia Sargas, Francisca Ferrer-Marín, Jorge Sánchez-Calero, Julián Sevilla, Elena Ruíz, Lucía Villalón, María del Mar Herráez, Rosalía Riaza, Elena Magro, Juan Luis Steegman, Chongwu Wang, Paula de Toledo, Valentín García-Gutiérrez, Rosa Ayala, Josep-Maria Ribera, Santiago Barrio & Joaquín Martínez-López. (2022) Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA. Scientific Reports 12:1.
Crossref
Crossref
Rajesh Sharma & Chinmay Jani. (2022) Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030. Annals of Hematology 101:7, pages 1523-1534.
Crossref
Crossref
Isamu Sugiura, Noriko DokiTomoko HataRyuko ChoToshiro ItoYouko SuehiroMasatsugu TanakaShinichi Kako, Mitsuhiro Matsuda, Hisayuki Yokoyama, Yuichi Ishikawa, Yasuhiro TaniguchiMaki HagiharaYukiyasu OzawaYasunori UedaDaiki HiranoToru SakuraMasaaki TsujiTsuyoshi KamaeHiroyuki Fujita, Nobuhiro HiramotoMasahiro OnodaShin FujisawaYoshihiro HattaNobuaki DobashiSatoshi NishiwakiYoshiko AtsutaYukio KobayashiFumihiko Hayakawa, Shigeki Ohtake, Tomoki NaoeYasushi Miyazaki. (2022) Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood Advances 6:2, pages 624-636.
Crossref
Crossref
Yun Ma, Guijie Guo, Tingting Li, Faxin Wen, Jianling Yang, Biao Chen, Xuefei Wang & Ji-Long Chen. (2022) A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes. Molecular Cancer 21:1.
Crossref
Crossref
Melissa A. Burns & Lewis B. Silverman. 2022. Clinical Management of Acute Lymphoblastic Leukemia. Clinical Management of Acute Lymphoblastic Leukemia
171
184
.
Anne Tierens, Tracy L. Stockley, Clinton Campbell, Jill Fulcher, Brian Leber, Elizabeth McCready, Peter J. B. Sabatini, Bekim Sadikovic & Andre C. Schuh. (2021) Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. Current Oncology 28:2, pages 1376-1387.
Crossref
Crossref
Pratik P. Patil, Esha Jafa & Mayank Aggarwal. (2021) Minimal Residual Disease in Acute Lymphoblastic Leukemia. Indian Journal of Medical and Paediatric Oncology 42:01, pages 071-076.
Crossref
Crossref
Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver Ottmann, Nicola Gökbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine A. Tuglus, Joan D. Morris & Anthony Stein. (2021) Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. European Journal of Cancer 146, pages 107-114.
Crossref
Crossref
Nitin Jain, Stefan Faderl, Hagop M. Kantarjian & Susan O'Brien. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
16
.
Stefania Stella, Enrico Marco Gottardi, Valeria Favout, Eva Barragan Gonzalez, Santa Errichiello, Silvia Rita Vitale, Carmen Fava, Luigia Luciano, Fabio Stagno, Francesco Grimaldi, Lucrezia Pironi, Claudia Sargas Simarro, Paolo Vigneri & Barbara Izzo. (2019) The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias. International Journal of Molecular Sciences 20:24, pages 6106.
Crossref
Crossref
Simona Soverini, Renato Bassan & Thomas Lion. (2019) Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Irene Della Starza, Sabina Chiaretti, Maria S. De Propris, Loredana Elia, Marzia Cavalli, Lucia A. De Novi, Roberta Soscia, Monica Messina, Antonella Vitale, Anna Guarini & Robin Foà. (2019) Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. Frontiers in Oncology 9.
Crossref
Crossref
Renato BassanJean-Pierre BourquinDaniel J. DeAngeloSabina Chiaretti. (2018) New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 36:35, pages 3504-3519.
Crossref
Crossref
Xiangyu Zhao, Xiaosu Zhao, Huan Chen, Yazhen Qin, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Xiaojun Huang & Ying-Jun Chang. (2018) Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 24:9, pages 1936-1943.
Crossref
Crossref
Elaine Vickers. 2018. A Beginner's Guide to Targeted Cancer Treatments. A Beginner's Guide to Targeted Cancer Treatments
259
312
.
Renato Bassan. (2017) Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia. The Lancet Haematology 4:8, pages e346-e347.
Crossref
Crossref
Daniel T. Barratt, Hannah K. Cox, Andrew Menelaou, David T. Yeung, Deborah L. White, Timothy P. Hughes & Andrew A. Somogyi. (2016) CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. Clinical Pharmacokinetics 56:8, pages 977-985.
Crossref
Crossref
Renato Bassan, Tamara Intermesoli, Annamaria Scattolin, Piera Viero, Elena Maino, Rosaria Sancetta, Francesca Carobolante, Francesca Gianni, Paola Stefanoni, Manuela Tosi, Orietta Spinelli & Alessandro Rambaldi. (2017) Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 17, pages S2-S9.
Crossref
Crossref
Cheng Zhang, Xi Zhang, Shi-Jie Yang & Xing-Hua Chen. (2017) Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Oncology Letters 13:4, pages 2059-2070.
Crossref
Crossref
Giovanni MartinelliNicolas BoisselPatrice ChevallierOliver OttmannNicola GökbugetMax S. ToppAdele K. FieldingAlessandro RambaldiEllen K. RitchieCristina PapayannidisLulu Ren SterlingJonathan BenjaminAnthony Stein. (2017) Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, pages JCO.2016.69.353.
Crossref
Crossref
Nitin Jain, Stefan Faderl, Hagop M. Kantarjian & Susan O'Brien. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
16
.
Haoyu Li, Yongfeng Wang, Zhenghu Chen, Jiaxiong Lu, Jessie Pan, Yang Yu, Yanling Zhao, Huiyuan Zhang, Ting Hu, Qing Liu & Jianhua Yang. (2016)
Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth
in vivo
. Oncotarget 8:4, pages 5874-5884.
Crossref
Crossref
Annamaria Petrungaro, Massimo Gentile, Carla Mazzone, Rosa Greco, Giuseppina Uccello, Anna Grazia Recchia, Laura De Stefano, Sabrina Bossio, Angela Palummo, Rosellina Morelli, Caterina Musolino, Fortunato Morabito & Ernesto Vigna. (2017) Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. Chemotherapy 62:6, pages 353-356.
Crossref
Crossref
Nicholas J. Short, Elias Jabbour, Koji Sasaki, Keyur Patel, Susan M. O’Brien, Jorge E. Cortes, Rebecca Garris, Ghayas C. IssaGuillermo Garcia-Manero, Rajyalakshmi Luthra, Deborah Thomas, Hagop Kantarjian & Farhad Ravandi. (2016) Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood 128:4, pages 504-507.
Crossref
Crossref
Kirsten Bleckmann & Martin Schrappe. (2016) Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. British Journal of Haematology 172:6, pages 855-869.
Crossref
Crossref
Behzad Kharabi Masouleh, Eric Chevet, Jens Panse, Edgar Jost, Michael O’Dwyer, Tim H. Bruemmendorf & Afshin Samali. (2015) Drugging the unfolded protein response in acute leukemias. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Elzbieta Pawlowska & Janusz Blasiak. (2015) DNA Repair—A Double-Edged Sword in the Genomic Stability of Cancer Cells—The Case of Chronic Myeloid Leukemia. International Journal of Molecular Sciences 16:11, pages 27535-27549.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2015) A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacological Research 100, pages 1-23.
Crossref
Crossref
Renato Bassan & Orietta Spinelli. (2015) Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy. Current Hematologic Malignancy Reports 10:2, pages 86-95.
Crossref
Crossref
Alessandro Morotti, Giovanna Carrà, Cristina Panuzzo, Sabrina Crivellaro, Riccardo Taulli, Angelo Guerrasio & Giuseppe Saglio. (2015) Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias. Advances in Hematology 2015, pages 1-6.
Crossref
Crossref
Orietta Spinelli, Manuela Tosi, Marie Lorena Guinea Montalvo, Barbara Peruta, Margherita Parolini, Anna Maria Scattolin, Elena Maino, Piera Viero, Alessandro Rambaldi & Renato Bassan. (2014) Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia. International Journal of Hematologic Oncology 3:6, pages 419-431.
Crossref
Crossref